Curis Valuation

Is CRIS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRIS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CRIS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CRIS's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRIS?

Key metric: As CRIS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CRIS. This is calculated by dividing CRIS's market cap by their current revenue.
What is CRIS's PS Ratio?
PS Ratio3.4x
SalesUS$10.26m
Market CapUS$34.12m

Price to Sales Ratio vs Peers

How does CRIS's PS Ratio compare to its peers?

The above table shows the PS ratio for CRIS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.6x
ICCC ImmuCell
1.2xn/aUS$28.9m
FBIO Fortress Biotech
0.6x55.9%US$44.4m
HCWB HCW Biologics
7.7x63.0%US$34.3m
DYAI Dyadic International
16.8x28.2%US$57.1m
CRIS Curis
3.4x41.1%US$34.1m

Price-To-Sales vs Peers: CRIS is good value based on its Price-To-Sales Ratio (3.4x) compared to the peer average (6.6x).


Price to Sales Ratio vs Industry

How does CRIS's PS Ratio compare vs other companies in the US Biotechs Industry?

128 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.6x21.4%
CRIS Curis
3.4x41.1%US$34.12m
GILD Gilead Sciences
4x2.4%US$112.40b
BIIB Biogen
2.4x1.3%US$23.01b
CRIS 3.4xIndustry Avg. 9.6xNo. of Companies128PS01632486480+
128 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.6x28.3%
CRIS Curis
3.4x-0.4%US$34.12m
No more companies

Price-To-Sales vs Industry: CRIS is good value based on its Price-To-Sales Ratio (3.4x) compared to the US Biotechs industry average (9.6x).


Price to Sales Ratio vs Fair Ratio

What is CRIS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRIS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.4x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: CRIS is expensive based on its Price-To-Sales Ratio (3.4x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRIS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.11
US$21.00
+410.9%
14.3%US$26.00US$18.00n/a4
Nov ’25US$4.18
US$21.00
+402.4%
14.3%US$26.00US$18.00n/a4
Oct ’25US$5.25
US$22.50
+328.6%
15.9%US$26.00US$18.00n/a4
Sep ’25US$5.53
US$22.50
+307.2%
15.9%US$26.00US$18.00n/a4
Aug ’25US$4.94
US$22.50
+355.5%
15.9%US$26.00US$18.00n/a4
Jul ’25US$6.38
US$22.50
+252.7%
15.9%US$26.00US$18.00n/a4
Jun ’25US$10.36
US$22.50
+117.2%
15.9%US$26.00US$18.00n/a4
May ’25US$15.99
US$21.75
+36.0%
21.2%US$26.00US$15.00n/a4
Apr ’25US$12.68
US$21.75
+71.5%
21.2%US$26.00US$15.00n/a4
Mar ’25US$10.07
US$21.75
+116.0%
21.2%US$26.00US$15.00n/a4
Feb ’25US$10.20
US$32.33
+217.0%
41.5%US$51.00US$20.00n/a3
Jan ’25US$12.75
US$32.33
+153.6%
41.5%US$51.00US$20.00n/a3
Dec ’24US$11.86
US$32.33
+172.6%
41.5%US$51.00US$20.00n/a3
Nov ’24US$4.71
US$103.67
+2,101.0%
65.8%US$200.00US$51.00US$4.183
Oct ’24US$6.59
US$103.67
+1,473.1%
65.8%US$200.00US$51.00US$5.253
Sep ’24US$11.58
US$126.67
+994.0%
45.3%US$200.00US$60.00US$5.533
Aug ’24US$16.32
US$126.67
+676.1%
45.3%US$200.00US$60.00US$4.943
Jul ’24US$16.60
US$146.67
+783.5%
42.2%US$200.00US$60.00US$6.383
Jun ’24US$16.36
US$146.67
+796.5%
42.2%US$200.00US$60.00US$10.363
May ’24US$16.60
US$146.67
+783.5%
42.2%US$200.00US$60.00US$15.993
Apr ’24US$11.92
US$146.67
+1,130.4%
42.2%US$200.00US$60.00US$12.683
Mar ’24US$12.60
US$146.67
+1,064.0%
42.2%US$200.00US$60.00US$10.073
Feb ’24US$14.50
US$146.67
+911.5%
42.2%US$200.00US$60.00US$10.203
Jan ’24US$11.00
US$146.67
+1,233.3%
42.2%US$200.00US$60.00US$12.753
Dec ’23US$15.86
US$226.67
+1,329.2%
70.0%US$440.00US$60.00US$11.863
Nov ’23US$16.89
US$273.33
+1,518.1%
58.0%US$440.00US$60.00US$4.713

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies